HealthWarehouse.com Inc (HEWA)
OTHER OTC:HEWA
Top Page
HealthWarehouse
(OTC:HEWA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$0.10
▼(-18.33% Downside)
Action:ReiteratedDate:04/03/26
The score is held back mainly by weak financial strength—especially persistent negative equity—and thin profitability despite a 2025 turnaround in earnings and cash flow. Technicals are moderately supportive with the stock above key moving averages and positive momentum, while valuation looks only average given limited margin strength and no dividend.
Positive Factors
DTC mail-order pharmacy model
The direct-to-consumer mail-order model creates durable customer convenience and recurring prescription demand, lowering reliance on brick-and-mortar footprints. Over months this supports stable unit economics and retention, aligning with structural shifts toward online pharmacy fulfillment.
Negative Factors
Negative stockholders' equity
Persistently negative equity is a structural balance-sheet weakness that constrains financing options and heightens insolvency risk if performance slips. It limits the company's ability to absorb shocks, pursue larger partnerships, or access capital on favorable terms in the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
DTC mail-order pharmacy model
The direct-to-consumer mail-order model creates durable customer convenience and recurring prescription demand, lowering reliance on brick-and-mortar footprints. Over months this supports stable unit economics and retention, aligning with structural shifts toward online pharmacy fulfillment.
Read all positive factors
HealthWarehouse (HEWA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.09M
Dividend YieldN/A
Average Volume (3M)2.08K
Price to Earnings (P/E)23.4
Beta (1Y)-0.44
Revenue Growth112.89%
EPS GrowthN/A
CountryUS
Employees121
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding42,649,000
10 Day Avg. Volume2,307
30 Day Avg. Volume2,084
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)-1.88
Price to Sales (P/S)0.13
P/FCF Ratio5.83
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.28
Enterprise Value/Ebitda5.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HealthWarehouse Business Overview & Revenue Model
Company Description
HealthWarehouse.com, Inc. operates an online and mail order pharmacy. The company markets a range of generic, brand name, and pet prescription medicines, as well as over-the-counter (OTC) medications and products. It sells its products in 50 state...
How the Company Makes Money
HealthWarehouse primarily makes money by dispensing and selling prescription medications through its mail-order pharmacy model. Revenue is generated when customers purchase prescription drugs (and potentially other pharmacy-related products offere...
HealthWarehouse Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
28
Negative
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 48.99M | 33.61M | 20.28M | 18.14M | 16.14M |
| Gross Profit | 17.14M | 13.69M | 12.17M | 11.94M | 11.13M |
| EBITDA | 931.00K | 338.42K | -1.28M | -559.33K | -224.76K |
| Net Income | 265.00K | -332.97K | -1.77M | -952.03K | -572.50K |
Balance Sheet | |||||
| Total Assets | 5.88M | 5.05M | 3.21M | 3.97M | 3.62M |
| Cash, Cash Equivalents and Short-Term Investments | 2.21M | 1.13M | 567.96K | 1.04M | 2.18M |
| Total Debt | 2.90M | 3.84M | 2.09M | 3.04M | 2.15M |
| Total Liabilities | 9.18M | 9.08M | 7.21M | 7.00M | 6.41M |
| Stockholders Equity | -3.30M | -4.04M | -4.01M | -3.03M | -2.79M |
Cash Flow | |||||
| Free Cash Flow | 1.06M | 565.36K | -473.81K | -1.14M | 313.64K |
| Operating Cash Flow | 1.16M | 705.26K | -163.84K | -624.45K | 400.51K |
| Investing Cash Flow | -95.23K | -139.90K | -309.97K | -512.85K | -86.86K |
| Financing Cash Flow | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 |
HealthWarehouse Technical Analysis
Negative
0.12
Price Trends
0.10
Negative
0.11
Negative
0.11
Negative
Market Momentum
<0.01
Positive
39.30
Neutral
67.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HEWA, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 39.30 is Neutral, neither overbought nor oversold. The STOCH value of 67.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HEWA.
HealthWarehouse Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $166.47M | -21.66 | -117.74% | ― | 30.71% | 73.43% | |
55 Neutral | $4.09M | 23.39 | ― | ― | 112.89% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $6.41M | -0.51 | -537.60% | ― | ― | 98.86% | |
41 Neutral | $49.65M | -1.59 | -122.10% | ― | -24.81% | -5344.15% | |
40 Underperform | $7.17M | -1.29 | -220.42% | ― | -41.03% | 35.71% |
* Healthcare Sector Average
HEWA
HealthWarehouse
0.10
0.02
20.00%
PETS
Petmed Express
2.32
-0.93
-28.62%
NDRA
ENDRA Life Sciences
5.17
0.09
1.77%
LFMD
LifeMD
3.47
-1.73
-33.27%
KTTA
Pasithea Therapeutics Corp
0.77
-0.32
-29.72%
HSCS
Heart Test Laboratories, Inc.
2.25
-0.80
-26.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.